SARS-CoV-2-neutralizing antibody treatment in patients with COVID-19 and immunodeficiency due to B-cell non-Hodgkin lymphoma

Blood Adv. 2022 Mar 8;6(5):1580-1584. doi: 10.1182/bloodadvances.2021006655.

Jakob J Malin^{1

2}, Veronica Di Cristanziano³, Carola Horn¹, Elisabeth Pracht¹, Jorge Garcia Borrega¹, Eva Heger³, Elena Knops^{3

4}, Rolf Kaiser³, Boris Böll¹, Clara Lehmann^{1

4}, Norma Jung¹, Peter Borchmann¹, Gerd Fätkenheuer¹, Florian Klein^{3

4}, Michael Hallek¹, Jan Rybniker^{1

2

4}

¹ Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
² Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine, University of Cologne, Cologne, Germany.
³ Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; and.
⁴ German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.

No abstract available

MeSH terms